Adding immunotherapy to chemotherapy can delay deterioration in health-related quality of life (HRQOL) for patients with metastatic non-small cell lung cancer (NSCLC), according to results from the phase 3 POSEIDON study.1

Researchers found that HRQOL outcomes were generally superior with tremelimumab plus durvalumab and chemotherapy (TDC) or durvalumab plus chemotherapy (DC), compared with chemotherapy alone.

These findings were presented at the 2022 European Lung Cancer Congress (ELCC).


Continue Reading

The POSEIDON trial (ClinicalTrials.gov Identifier: NCT03164616) enrolled 1013 patients who had stage IV NSCLC without EGFR or ALK alterations. Patients were randomly assigned to receive TDC (n=338), DC (n=338), or platinum-based chemotherapy alone (n=337).

In the trial’s previously reported efficacy analysis, both TDC and DC significantly improved progression-free survival over chemotherapy alone.2 TDC also improved overall survival compared with chemotherapy alone.

For the current analysis, researchers assessed HRQOL in the 3 treatment arms using the QLQ-C30 and QLQ-LC13 questionnaires. Compliance with the questionnaires was 60% or higher up to 88 weeks in the TDC arm, up to 64 weeks in the DC arm, and up to 24 weeks in the chemotherapy-alone arm. Baseline patient-reported outcome scores were largely similar across the 3 treatment arms.

Hazard ratios (HRs) suggested a longer time to deterioration with both TDC and DC relative to chemotherapy alone for:

  • Global health status (HR, 0.78 and 0.79, respectively)
  • Physical functioning (HR, 0.75 and 0.70, respectively)
  • Fatigue (HR, 0.90 and 0.83, respectively)
  • Cough (HR, 0.91 and 0.87, respectively)
  • Dyspnea (HR, 0.77 and 0.81, respectively)
  • Chest pain (HR, 0.85 and 0.86, respectively).

Time to deterioration for appetite loss favored TDC over chemotherapy alone (HR, 0.94) but favored chemotherapy alone over DC (HR, 1.05).

The researchers also found that improvements in the aforementioned outcomes were greater with TDC or DC relative to chemotherapy alone.

Disclosures: This research was sponsored by AstraZeneca. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.

References

1. Garon EB, Cho BC, Luft A, et al. Patient-reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON. Presented at ELCC 2022; March 30 – April 2, 2022. Abstract 5MO.

2. Johnson M, Cho BC, Luft A, et al. Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC; Results from the phase 3 POSEIDON study. 2021;16(10 Suppl):S844. doi:10.1016/j.jtho.2021.08.029